Company News: Medivation, Hacker Group and HealthHG

Share this article:
San Francisco-based biotech Medivation said it will cut 23 positions – a fifth of its staff – as part of a cost-cutting exercise in the wake of the failure of Alzheimer's drug candidate dimebon, which the firm was partnering with Pfizer on. Medivation will continue to work on Alzheimer's and Huntington disease applications for dimebon and on its MDV3100 for prostate cancer.

Hacker Group, a Seattle-based digital and direct marketing shop, announced that it is launching a health insurance marketing practice, dubbed HealthHG. The practice will be led by VP account services Jill Kaufman and chief strategist Tom Reid. Clients include Highmark Blue Shield, EmblemHealth and Blue Cross Blue Shield of Alabama.
Share this article:
You must be a registered member of MMM to post a comment.
close

Next Article in Business Briefs

Email Newsletters

MM&M EBOOK: PATIENT ACCESS

Patient access to pharmaceuticals is a tale of two worlds—affordability has improved for the majority, while the minority is hampered by cost, distribution and red tape. To provide marketers with a well-rounded perspective, MM&M presents this e-book chock full of key insights. Click here to access it.

More in Business Briefs

Monday Moves: September 15

Hires and promotions for manufacturers, regulatory and agencies

Kantar acquires Evidências, expands Brazilian presence

The company's acquisition signals the growing importance of understanding the Brazilian healthcare market and evidence-based healthcare management services.

Study says statins not enough for diabetic hearts

Researchers using an experimental test have discovered that the 50% of surveyed diabetics may also have undetected heart muscle damage.